Combination therapies for patients with metastatic renal cell carcinoma

Affiliations

¹ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
³ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy; Medical Oncology Department, University of Milan, Milan, Italy.

Comment

Giuseppe Procopio et al. Lancet Oncol. 2018 Mar.

. 2018 Mar;19(3):281-283.

doi: 10.1016/S1470-2045(18)30092-5. Epub 2018 Feb 10.

¹ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
³ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy; Medical Oncology Department, University of Milan, Milan, Italy.

No abstract available

Comment on

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK. Atkins MB, et al. Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10. Lancet Oncol. 2018. PMID: 29439857 Free PMC article. Clinical Trial.